In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.
Advertisement

Related Content

Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
Achillion HCV Candidate Shows Promising Phase I Results In Once-Daily Dosing
Achillion HCV Candidate Shows Promising Phase I Results In Once-Daily Dosing

Topics

Advertisement
UsernamePublicRestriction

Register

PS004604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel